MM is the second most common hematological cancer and BCMA, a protein present in high concentrations on a small subset of healthy blood cells and multiple myeloma cells, is the most extensively studied CAR target for myeloma. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.